The therapeutic application of Нейрокард (Ethylmethylhydroxypyridine Succinate) focuses on providing supportive relief across several clinical domains characterized by heightened physical or emotional symptoms related to systemic imbalance.

This therapeutic approach involves addressing neurological and vascular symptoms in conditions associated with significant symptomatic burden.

It is commonly used across domains involving symptomatic discomfort, including conditions like chronic cerebral ischemia (discirculatory encephalopathy), anxiety syndromes, post-event functional deficits after stroke or TBI, and supportive care in primary open-angle glaucoma. The medication helps address symptom clusters that may become intense or disruptive, such as impaired memory and attention, persistent dizziness and headache, and significant physical or mental fatigue.

“The symptomatic support provided is helpful for patients coping more steadily with temporary functional strain and discomfort.”

The application of the compound provides relief when symptoms interfere with routine activities and contributes to easing distress during symptomatic periods. It is relevant when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.

---

Quick Fact: Relief for Chronic Fatigue and Cognitive Strain

Who Can and Cannot Use Нейрокард?

The population eligibility for Нейрокард (Ethylmethylhydroxypyridine Succinate) is determined by official regulatory documents, primarily defining groups for whom the medicine is strictly contraindicated.

---

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults (18 years of age and older).
Populations for whom use is contraindicated	Individuals with acute hepatic failure or acute renal failure; individuals with known hypersensitivity to the active substance or excipients.
Age-related eligibility rules	Pediatric Use (Children and adolescents under 18) is contraindicated due to insufficient clinical data.
Condition-specific eligibility rules	Acute Renal Failure and Acute Hepatic Failure are formal, absolute contraindications.
Pregnancy and lactation eligibility status	Contraindicated during pregnancy and breastfeeding due to a documented lack of sufficient data on the drug's safety in these groups.

---

Eligibility Classifications

Category	Regulatory Status
Eligibility severity classification	Contraindicated (highest level of prohibition).

The regulatory structure prohibits the drug's use based on acute organ dysfunction, patient age, reproductive status, and allergy status, ensuring allowed use is limited to the adult population without these specific health conditions or risk factors.

Interactions with other medicines and products

The official regulatory documents for Ethylmethylhydroxypyridine Succinate define specific interaction patterns primarily related to pharmacodynamic enhancement and a pharmacokinetic pathway. All documented interaction information is based strictly on data published by national medicines agencies.

---

Documented Interaction Patterns

Type	Interacting Substances / Categories	Official Regulatory Outcome
Pharmacodynamic	Anxiolytics, Anticonvulsants, Neuroleptics, Narcotic Analgesics, Levodopa	Co-administration leads to the potentiation (enhancement) of the therapeutic effects of these agents.
Pharmacokinetic	Substrates of CYP3A4	The drug is documented as an inducer of the CYP3A4 enzyme, potentially leading to a reduction in the systemic exposure and therapeutic effect of co-administered CYP3A4 substrates.

---

Drug-Substance Interaction

The prescribing information documents an interaction with Ethanol (Alcohol). Concurrent use results in the potentiation of the psychoactive effects of alcohol.

No medicinal products are listed as strictly contraindicated based solely on interaction data in the regulatory labeling. The documentation also does not mandate specific timing separation rules for administration with other medicines. The overall interaction structure is defined by the requirement to account for the officially documented enhancement of central nervous system effects when this product is used concurrently with other CNS-acting agents.

How Нейрокард works: Mechanism of Action

Нейрокард acts as a non-dihydropyridine calcium channel blocker by selectively targeting and inhibiting the L-type voltage-gated calcium channels ( Cav1.2) found on the membranes of cardiac muscle and vascular smooth muscle cells. This action limits the transmembrane influx of calcium ions ( Ca^2+), which are essential for cellular depolarization and excitation-contraction coupling.

Within the myocardium, this modification of Ca^2+ flux results in modified myocardial contractility and affects the heart’s electrophysiological activity. It specifically modulates conduction within the sino-atrial (SA) and atrioventricular (AV) nodes, slowing the rate of electrical signal propagation through the cardiac conduction system.

In the vasculature, the inhibition of Ca^2+ influx causes relaxation of peripheral and coronary vascular smooth muscle. This systemic pathway effect decreases both systemic and coronary vascular resistance, resulting in a reduction in cardiac oxygen demand.

How to Use Нейрокард

The administration of Нейрокард (Ethylmethylhydroxypyridine Succinate) follows specific parameters regarding route, dosage, frequency, and preparation. The medicine is available for both oral use (tablets) and parenteral use (solution for injection).

Approved Administration Routes

The drug is administered via three primary routes:

• Oral: For tablets.
• Intramuscular (IM): For solution for injection.
• Intravenous (IV): For solution for injection, delivered as a slow drip infusion or slow jet infusion.

Official Dosing and Frequency

Dosage parameters are defined for various administration methods. For oral use, the dose typically ranges from 125 mg to 250 mg and is administered up to three times per day, with a maximum daily dose of 750 mg. For parenteral use, doses range from 100 mg to 500 mg up to four times daily, not exceeding a general maximum of 1200 mg per day.

Use Patterns and Preparation

Treatment often begins with an initial intensive course of IV/IM injection (typically 10-15 days), after which a transition to the oral tablet form is a common pattern for continuation (usually 2-8 weeks). For the IV drip, the solution is diluted in 100-150 ml of 0.9% sodium chloride or 5% dextrose solution and infused slowly at 40-60 drops per minute. To conclude a course, the dose is gradually reduced over 2-3 days.

Research Evidence / Overview of Studies for Нейрокард

Evidence for Use in Acute and Early Recovery Ischemic Stroke

This section will summarize the structure of multicenter randomized controlled trials (RCTs) that have evaluated the use of Ethylmethylhydroxypyridine Succinate in patients during the acute and early recovery phases following an ischemic stroke, focusing on the functional and neurological outcomes researchers chose to measure.

Research exploring the substance in stroke involves international, randomized, double-blind, placebo-controlled clinical trials, which are considered a rigorous type of study design. These trials research examined the drug's use alongside standard medical care in adult patients, typically focusing on cases of moderate severity. The outcomes reflecting daily functioning or activity level that were measured included changes in patient disability status (Modified Rankin Scale, mRS), the severity of neurological symptoms (NIHSS scale), and changes in mobility (Rivermead Mobility Index).

The studies reported patterns observed over the treatment period, comparing the group receiving the substance with the group receiving a placebo. The data show patterns related to patient independence in everyday life and the change of neurological symptoms during the intermediate follow-up period.

Evidence for Use in Chronic Cerebral Ischemia (Discirculatory Encephalopathy)

This part will describe the clinical studies, including controlled trials, that have examined the substance's supportive role in managing symptoms of Chronic Cerebral Ischemia (CCI), such as cognitive strain, anxiety, and asthenia, and will detail the scale-based outcomes that were evaluated in these populations.

Studies exploring this substance in the context of CCI include both randomized controlled trials and various comparative clinical studies. Research focused on symptom/outcome axes that capture functional imbalance, such as patient-reported outcomes describing perceived discomfort related to physical and mental fatigue (asthenia), headache, and dizziness. Studies reported that the measured scores for symptoms like asthenia and anxiety varied when comparing patients receiving the substance to those in a control group.

Long-Term Studies and Follow-up Durations

The primary body of research exploring the substance’s use is based on intermediate-term follow-up periods, usually lasting between 60 and 71 days. Long-term effects are not fully established beyond these initial two-to-three-month observational periods. There is currently limited information for long-term outcomes regarding the durability of the observed functional measurements or data on the prevention of future episodes.

Key Studies & References

1. Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) (ClinicalTrials.gov)

Common questions about Нейрокард (FAQ)

---

Q: Does this medicine only treat heart and circulatory issues?

Official regulatory documents classify Нейрокард as a neuroprotective, antioxidant, and antihypoxic agent. Its classification is focused on properties that support nerve cell resilience and stability. While the mechanism of action includes effects on the cardiovascular system, its established indications often relate to conditions involving cerebral ischemia (issues with blood flow to the brain).

---

Q: Can Нейрокард be used to help with general fatigue or lack of energy?

Research evidence indicates that studies have examined the drug’s supportive role in managing symptoms like asthenia (physical and mental fatigue) within the context of Chronic Cerebral Ischemia (CCI). Official documentation examines this substance’s use within this specific condition, and information is not available for treating general, undiagnosed fatigue.

---

Q: Are there any known long-term safety concerns with taking Нейрокард?

The available research evidence generally focuses on intermediate-term follow-up periods, usually lasting between two to three months. Official documents note that long-term effects are not fully established beyond these initial observational periods regarding the durability of the observed functional effects.

---

Q: What are the non-clinical signs that Нейрокард is actually working?

Clinical trials examining the drug's use in cerebral conditions measured outcomes that relate to a patient's daily life. These outcomes included changes in mobility, the severity of neurological symptoms, and overall improvements in patient independence and functional status in everyday activities.

---

Q: Does Нейрокард interact with common cold or flu medicines?

Regulatory documents state that the drug enhances the therapeutic effects of certain central nervous system (CNS) agents, such as anxiolytics and narcotic analgesics. Due to the potential for overlap, a healthcare professional can assess whether ingredients in cold or flu medicines fall into these CNS-acting categories.

---

Q: What is the shelf life of Нейрокард and how should I store it?

The medicine must be stored in its original container, in a place protected from light, at a temperature not exceeding 25 C (77 F), and must not be frozen. Official documents indicate the drug preserves its specific activity for approximately three years.

---

Q: Can people with low blood pressure safely take Нейрокард?

The drug's mechanism includes decreasing systemic vascular resistance, which can affect blood pressure. Regulatory text documents that the drug may involve transient effects on blood pressure, particularly with the injectable form. Pre-existing low blood pressure (hypotension) is not listed as an absolute contraindication in official documents.

---

Q: How quickly should I expect to notice any effects from Нейрокард?

When taken orally, the drug is rapidly absorbed, with the peak concentration in the bloodstream occurring shortly after administration. For acute conditions, official instructions involve an intensive course of injection for the first 10 to 14 days before transitioning to tablets. This administration protocol may suggest a gradual process toward achieving the intended effects.

---

Q: What is the typical duration of action for one dose?

According to pharmacokinetic data, the substance is quickly distributed to organs and tissues throughout the body. The mean residence time of the drug in the body after oral administration is documented as approximately 4.9 to 5.2 hours.

---

Q: Are there any known food interactions with Нейрокард?

Official regulatory documents for this specific product do not contain specific warnings or instructions regarding taking the drug with food. The documented interaction warnings are primarily focused on how it interacts with other medications and with Ethanol (Alcohol).

---

Q: Is a prescription always required for Нейрокард, or is it available over-the-counter?

Official regulatory documents reference the drug’s use in standard medical care settings. The requirement to follow specific, detailed instructions regarding the route, dosage, and frequency of use suggests its status as a prescribed medical product.

---

Q: Is Нейрокард approved by major international regulatory bodies?

The active ingredient, Ethylmethylhydroxypyridine Succinate, is primarily authorized via national regulatory procedures in the countries where it is marketed. It is not listed as a medicine that has been centrally evaluated and authorized by certain international bodies like the European Medicines Agency (EMA).

---

Q: Can Нейрокард be used in combination with ACE inhibitors or beta-blockers?

Official instructions document the drug's use as part of a complex therapy for certain conditions, such as acute myocardial infarction. This complex therapy is documented to occur alongside traditional treatments, including ACE inhibitors and beta-blockers.

---

Q: Is it safe to discontinue Нейрокард use without consulting a healthcare provider?

Official administration instructions stipulate that to conclude any course, the dose must be gradually reduced over a period of two to three days. This procedure is established as the final step in the documented treatment regimen.

The storage and disposal of Нейрокард (Ethylmethylhydroxypyridine Succinate) must strictly follow the conditions specified in the official regulatory labeling.

Storage & Disposal Profile

The medicine is required to be stored in a place protected from light at a temperature not exceeding 25 C (77 F). It is mandatory to keep the product in its original container to ensure protection from environmental factors and must not be frozen, particularly the Solution for Injection. Any solution for injection is generally required to be used immediately after opening the ampoule.

Regulatory documents stipulate that the product must be stored out of the sight and reach of children. Unused or expired medication must be handled according to local regulatory disposal requirements and should not be discarded into wastewater or household trash.